Life-saving study results lift Bayer/J&J clot drug

ORLANDO, Florida (Reuters) – Data showing the life- saving benefits of a very low dose of a new blood clot preventer could alter future treatment of patients who suffer from acute coronary syndrome and provide a boost for the drug’s makers Bayer AG and Johnson & Johnson.